DK1069890T3 - Inkorporering af aktive substanser i bærematrikser - Google Patents

Inkorporering af aktive substanser i bærematrikser

Info

Publication number
DK1069890T3
DK1069890T3 DK99924076T DK99924076T DK1069890T3 DK 1069890 T3 DK1069890 T3 DK 1069890T3 DK 99924076 T DK99924076 T DK 99924076T DK 99924076 T DK99924076 T DK 99924076T DK 1069890 T3 DK1069890 T3 DK 1069890T3
Authority
DK
Denmark
Prior art keywords
incorporation
active substances
carrier matrices
matrices
carrier
Prior art date
Application number
DK99924076T
Other languages
Danish (da)
English (en)
Inventor
Marie-Louise Andersson
Catherine Boissier
Anne Marie Juppo
Anette Larsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1069890T3 publication Critical patent/DK1069890T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/04Solvent extraction of solutions which are liquid
    • B01D11/0403Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]
    • Y10T428/2985Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Nozzles (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK99924076T 1998-04-14 1999-04-09 Inkorporering af aktive substanser i bærematrikser DK1069890T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801287A SE9801287D0 (sv) 1998-04-14 1998-04-14 Incorporation of active substances in carrier matrixes

Publications (1)

Publication Number Publication Date
DK1069890T3 true DK1069890T3 (da) 2006-08-28

Family

ID=20410946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99924076T DK1069890T3 (da) 1998-04-14 1999-04-09 Inkorporering af aktive substanser i bærematrikser

Country Status (31)

Country Link
US (1) US6372260B1 (xx)
EP (1) EP1069890B1 (xx)
JP (1) JP2002511400A (xx)
KR (1) KR100600691B1 (xx)
CN (1) CN1201728C (xx)
AR (1) AR019262A1 (xx)
AT (1) ATE329580T1 (xx)
AU (1) AU744874B2 (xx)
BR (1) BR9909636A (xx)
CA (1) CA2327522C (xx)
CY (1) CY1105154T1 (xx)
CZ (1) CZ20003784A3 (xx)
DE (1) DE69931904T2 (xx)
DK (1) DK1069890T3 (xx)
EE (1) EE200000595A (xx)
ES (1) ES2267268T3 (xx)
HU (1) HUP0102305A3 (xx)
ID (1) ID29286A (xx)
IL (1) IL138635A0 (xx)
IS (1) IS5656A (xx)
NO (1) NO329145B1 (xx)
NZ (1) NZ507190A (xx)
PL (1) PL344077A1 (xx)
PT (1) PT1069890E (xx)
RU (1) RU2208435C2 (xx)
SE (1) SE9801287D0 (xx)
SK (1) SK14112000A3 (xx)
TR (1) TR200002960T2 (xx)
TW (1) TW542724B (xx)
WO (1) WO1999052507A1 (xx)
ZA (1) ZA992549B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
WO2001045731A1 (en) * 1999-12-21 2001-06-28 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
FR2824754B1 (fr) * 2001-05-15 2004-05-28 Separex Sa Procede d'obtention de particules solides a partir d'au moins un produit hydrosoluble
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
KR100979877B1 (ko) * 2001-09-28 2010-09-02 뉴트라슈틱스 인코포레이티드 생물학적 성분의 전달 시스템
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US7455797B2 (en) * 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
CA2523883C (en) * 2003-04-29 2012-01-03 Akzo Nobel N.V. Antisolvent solidification process
CA2524773C (en) 2003-05-08 2014-04-08 Nektar Therapeutics Uk Ltd Particulate coformulations of active substances with excipients
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
WO2005022603A2 (en) * 2003-09-02 2005-03-10 Integral Technologies, Inc. Low cost conductive containers manufactured from conductive loaded resin-based materials
GB0602637D0 (en) * 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
WO2007133750A2 (en) * 2006-05-12 2007-11-22 The Board Of Trustees Of The Leland Stanford Junior University Encapsulated nanoparticles for drug delivery
FR2900845B1 (fr) * 2006-05-15 2009-03-06 Commissariat Energie Atomique Procede et dispositif de synthese de particules organiques ou inorganiques enrobees
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
US20080260852A1 (en) * 2007-01-23 2008-10-23 Ferro Pfanstiehl Laboratories, Inc. Supercritical fluid extraction produced by in-line homogenization
US7745566B2 (en) * 2007-01-23 2010-06-29 Ferro Corporation Methods for the purification of polymers
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
KR102170146B1 (ko) * 2019-03-05 2020-10-26 서울대학교산학협력단 Pca 공정을 이용한 배양액의 결정화 장치 및 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation

Also Published As

Publication number Publication date
AU4066399A (en) 1999-11-01
JP2002511400A (ja) 2002-04-16
ID29286A (id) 2001-08-16
US6372260B1 (en) 2002-04-16
ATE329580T1 (de) 2006-07-15
KR20010042660A (ko) 2001-05-25
TR200002960T2 (tr) 2000-12-21
WO1999052507A1 (en) 1999-10-21
CA2327522A1 (en) 1999-10-21
SE9801287D0 (sv) 1998-04-14
HUP0102305A3 (en) 2003-04-28
PL344077A1 (en) 2001-09-24
IL138635A0 (en) 2001-10-31
BR9909636A (pt) 2000-12-19
DE69931904T2 (de) 2006-12-21
CN1201728C (zh) 2005-05-18
NO20005150D0 (no) 2000-10-13
PT1069890E (pt) 2006-09-29
AR019262A1 (es) 2002-02-13
TW542724B (en) 2003-07-21
RU2208435C2 (ru) 2003-07-20
EP1069890B1 (en) 2006-06-14
SK14112000A3 (sk) 2001-07-10
CY1105154T1 (el) 2010-03-03
NZ507190A (en) 2002-02-01
CZ20003784A3 (cs) 2001-08-15
IS5656A (is) 2000-10-11
NO329145B1 (no) 2010-08-30
HUP0102305A2 (hu) 2001-12-28
DE69931904D1 (de) 2006-07-27
ES2267268T3 (es) 2007-03-01
EP1069890A1 (en) 2001-01-24
NO20005150L (no) 2000-12-08
EE200000595A (et) 2002-04-15
KR100600691B1 (ko) 2006-07-19
AU744874B2 (en) 2002-03-07
CN1309555A (zh) 2001-08-22
ZA992549B (en) 1999-10-14
CA2327522C (en) 2008-03-25

Similar Documents

Publication Publication Date Title
DK1069890T3 (da) Inkorporering af aktive substanser i bærematrikser
DE69819481D1 (de) Formulierungen von clarithromycin mit verlängerter wirkstoff-freisetzung
ID29021A (id) Komposisi galantamina pelepasan terkontrol
DE69941116D1 (de) G von gdf-8
ATE260113T1 (de) Teriparatidhaltige stabilisierte lösungen
DE69832516D1 (de) Isoflavon-enthaltende zusammensetzungen
DE69836106D1 (de) Stanolester enthaltende Zusammensetzungen
DE69827744D1 (de) Polybuten-1 enthaltende polyolefinzusammensetzung
EE200100131A (et) Süstelahuste parem stabiilsus
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
DK1066292T3 (da) Metallocorrinoider som biologisk kompatible bærere af farmakologiske midler
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
DE59910255D1 (de) Wischerträger
ID24677A (id) Kombinasi senyawa aktif fungisidal
DK1155050T3 (da) Fremstilling af polyolefin
DE69822559D1 (de) Siliconzusammensetzung
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
ID22406A (id) Komposisi-komposisi umpan racun
DE69806145D1 (de) 3-alkylcycloalkanole enthaltende reichstoffkompositionen
IS5155A (is) Fjölgervingur af zópólrestat mónóhýdrati
IS5821A (is) Kristalluð form af ósanetant
DK1001962T3 (da) Fremstilling af avermectinforbindelser
DK1088010T3 (da) Fremstilling af polyolefiner
ATE290538T1 (de) Zusammensetzungen enthaltendes biologisch aktives silizium
DE69906796T2 (de) Dimeticon enthaltende aciclovirzusammensetzungen